Abstract 2703
Background
Uveal melanoma (UM) is a rare cancer that arises from melanocytes in the uveal tract of the eye. Despite effective treatment for primary UM, > 50% of patients develop metastatic disease. There is currently no effective treatment for metastatic UM and median life expectancy is < 8 months. About 90% of UM are characterised by mutations in the GNAQ or GNA11 GTPases and several signalling cascades downstream of G-protein activation have been identified as potentially targetable. These include the protein kinase C (PKC), mitogen activated protein kinase (MAPK), phosphatidylinositol-3-kinases (PI3K), mammalian target of rapamycin (mTOR), and YES-associated protein (YAP) pathways. Aim to understand the relative contribution of oncogenic signaling pathways in proliferation and survival of UM.
Methods
The response 11 UM cell lines to 6 selective inhibitors was investigated using cell viability assays and cell cycle analyses by flow cytometry. Inhibition of selected pathways was examined using Western analysis of downstream effector proteins. The inhibitors used in this study included PKC inhibitors (AEB071 and LXS196), MEK inhibitor (trametinib), PI3K/mTOR inhibitor (BEZ235), YAP inhibitor (verteporfin) and ARF6 inhibitor (NAV2729).
Results
PKC inhibitors were most effective with 8 GNAQ/11 mutant UM cell lines showing some degree of sensitivity to each of the inhibitors, although sensitivity was usually associated with proliferative arrest rather than cell death. (see Table) Expression levels of pMARCKS and pERK were strongly inhibited by PKC inhibitors, however inhibition of these effector proteins did not reflect the degree of UM cell sensitivity.Table:
21P Summary of UM cell lines to each inhibitor. Combined result of cell viability assay and cell cycle analysis
Cell Line | Mutation | Trametinib | BEZ235 | NAV2729 | AEB071 | Verteporfin | LXS196 |
---|---|---|---|---|---|---|---|
Mel270 | GNAQ | sensitive | sensitive | sensitive | sensitive | sensitive | sensitive |
OMM1 | GNA11 | resistant | sensitive | intermediate sensitivity | sensitive | sensitive | sensitive |
92.1 | GNAQ | resistant | intermediate sensitivity | sensitive | intermediate sensitivity | sensitive | intermediate sensitivity |
Mel202 | GNAQ | resistant | intermediate sensitivity | sensitive | intermediate sensitivity | sensitive | intermediate sensitivity |
OMM1.3 | GNAQ | resistant | intermediate sensitivity | resistant | intermediate sensitivity | resistant | intermediate sensitivity |
OMM1.5 | GNAQ | resistant | resistant | resistant | intermediate sensitivity | resistant | intermediate sensitivity |
MP41 | GNA11 | resistant | resistant | resistant | intermediate sensitivity | resistant | intermediate sensitivity |
MP46 | GNAQ | resistant | resistant | resistant | resistant | resistant | intermediate sensitivity |
MP38 | GNAQ | resistant | resistant | resistant | resistant | resistant | resistant |
Mel290 | Nil | resistant | intermediate sensitivity | resistant | resistant | resistant | resistant |
Mel285 | Nil | resistant | resistant | resistant | resistant | resistant | resistant |
Conclusions
The sensitivity of GNAQ/11 mutation UM cell lines to 6 targeted drugs is heterogeneous and no single dominant signalling pathway was identified. This suggest that multiple, independent signal pathways contribute to the survival of UM. Thus, inhibition of any single pathway is unlikely to be effective in the treatment of majority of metastatic UM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2459 - Does bevacizumab increase joint pain ? Preliminary results of BEVARTHRALGIA Study
Presenter: Vauleon Enora
Session: Poster Display session 1
Resources:
Abstract
4913 - Prostatic cancer androgen deprivation therapy and bone health in carcinoma prostate.
Presenter: Gouri Shankar Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
1352 - Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)
Presenter: Michael Mark
Session: Poster Display session 1
Resources:
Abstract
6002 - Infection-Related Mortality in Different Types of Cancers
Presenter: Mohamed Gouda
Session: Poster Display session 1
Resources:
Abstract
5643 - Survival Trends in Critically ill Oncology Patients: impact of patient’s eligibility to post-ICU chemotherapy
Presenter: Edith Borcoman
Session: Poster Display session 1
Resources:
Abstract
3097 - Development and validation of a multivariable prediction model for 6-month mortality in older cancer patients: the GeriAtrIc-Tumor Score of PrEdiction for Early Death (GAIT SPEED)
Presenter: Angeli Angeli
Session: Poster Display session 1
Resources:
Abstract
856 - A Longitudinal Tracking and Quantitative Assessment of Paclitaxel-Induced Peripheral Neurotoxicity
Presenter: Ayumu Matsuoka
Session: Poster Display session 1
Resources:
Abstract
1662 - Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)
Presenter: Trudi Schaper
Session: Poster Display session 1
Resources:
Abstract
2766 - The Validity of Evaluations for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Presenter: Teppei Yamada
Session: Poster Display session 1
Resources:
Abstract
5683 - Prevention of chemoradiation-related mucositis in patients with head and neck cancer using dexamethasone-based mouthwash: A phase II randomized double-blind, placebo-controlled study
Presenter: Naiyarat Prasongsook
Session: Poster Display session 1
Resources:
Abstract